Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1443-1450

  Ma, Shuai ^a   Qu, Wenzhi ^a   Mao, Liang ^a   Zhu, Zhi ^a   Jia, Lanling ^a   Zhao, Lei ^a   Zheng, Xinyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Drosophila melanogaster multi substrate deoxyribonucleoside kinase; Oncolytic adenovirus; Suicide gene; Virus therapy

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ADENOVIRUS VECTOR; DEOXYRIBONUCLEOSIDE KINASE; GEMCITABINE; ONCOLYTIC ADENOVIRUS; PHOSPHOTRANSFERASE; THYMINE ARABINOSIDE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOPATHOGENIC EFFECT; DROSOPHILA MELANOGASTER; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR CELL; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYTOPATHOGENIC EFFECT, VIRAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; NUCLEOSIDES; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TRANSGENES; VIRUS REPLICATION;

EID: 84863403875     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1665     Document Type: Article

References (30)

1. Winawer SJ: Screening of colorectal cancer: progress and problems. Recent Results Cancer Res 166: 231-244, 2005.
2. Lu JB, Sun XB, Dai DX, et al: Epidemiology of gastroenterologic cancer in Henan Province, China. World J Gastroenterol 9: 2400-2403, 2003.
3. Yiu HY, Whittemore AS and Shibata A: Increasing colorectal cancer incidence rates in Japan. Int J Cancer 109: 777-781, 2004. (Pubitemid 38405628)
4. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
5. Osaki T, Tanio Y, Tachibana I, et al: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258-5261, 1994. (Pubitemid 24336009)
6. Moolten FL: Drug sensitivity (suicide) genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279-287, 1994.
7. Lengler J, Omann M, Duvier D, et al: Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: implications for gene directed enzyme prodrug therapy. Biochem Pharmacol 72: 893-901, 2006. (Pubitemid 44301048)
8. Cai X, Zhou J, Chang Y, Sun X, Li P and Lin J: Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric alpha-fetoprotein promoter. Cancer Lett 264: 71-82, 2008.
9. Zheng X, Johansson M and Karlsson A: Bystander effects of cancer cell lines transduced with the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster and synergistic enhancement by hydroxyurea. Mol Pharmacol 60: 262-266, 2001. (Pubitemid 32678290)
10. Zheng X, Johansson M and Karlsson A: Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 275: 39125-39129, 2000. (Pubitemid 32058928)
11. Zheng X, Johansson M and Karlsson A: Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol. Biochem Biophys Res Commun 289: 229-233, 2001. (Pubitemid 33108819)
12. Roth JA and Cristiano RJ: Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89: 21-39, 1997. (Pubitemid 26428075)
13. Vile RG, Russell SJ and Lemoine NR: Cancer gene therapy: hard lessons and new courses. Gene Ther 7: 2-8, 2000. (Pubitemid 30077141)
14. Zheng X, Rao XM, Snodgrass C, et al: Adenoviral E1a expression levels affect virus-selective replication in human cancer cells. Cancer Biol Ther 4: 1255-1262, 2005.
15. Sangro B, Mazzolini G, Ruiz J, et al: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389-1397, 2004. (Pubitemid 41103620)
16. Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781-787, 2001. (Pubitemid 32691631)
17. Zhang Q, Chen G, Peng L, et al: Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 12: 6523-6531, 2006. (Pubitemid 44799727)
18. Liu TC and Kirn D: Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 15: 877-884, 2008.
19. Kirn DH and Thorne SH: Targeted and armed oncolytic pox-viruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71, 2009.
20. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645, 1997. (Pubitemid 27264973)
21. Reid T, Warren R and Kirn D: Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9: 979-986, 2002. (Pubitemid 35462561)
22. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE and Wold WS: Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 74: 6147-6155, 2000. (Pubitemid 30412986)
23. Hermiston T: Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 105: 1169-1172, 2000.
24. He XP, Su CQ, Wang XH, et al: E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett 285: 89-98, 2009.
25. Arner ES, Spasokoukotskaja T and Eriksson S: Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 188: 712-718, 1992.
26. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
27. Hermiston TW and Kuhn I: Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9: 1022-1035, 2002. (Pubitemid 35462564)
28. Wildiers J and De Clercq E: Oral (E)-5-(2-bromovinyl)-2′- deoxyuridine treatment of severe herpes zoster in cancer patients. Eur J Cancer Clin Oncol 20: 471-476, 1984. (Pubitemid 14138851)
29. Hui YF and Reitz J: Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54: 162-170, 1997. (Pubitemid 27058210)
30. Leitner S, Sweeney K, Oberg D, et al: Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 15: 1730-1740, 2009.